

Haematologica  
HAEMATOL/2019/234476  
Version 3

TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma

Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Asuka Oda, Ariunzaya Bat-Erdene, Takeshi Harada, Shingen Nakamura, Mohammad Ashtar, So Shimizu, Masami Iwasa, Kimiko Sogabe, Masahiro Oura, Shiro Fujii, Kumiko Kagawa, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto, and Masahiro Abe

Disclosures: This work was supported in part by JSPS KAKENHI Grant Numbers JP18K08329, JP16K11504, JP17KK0169, JP18H06294; and Aki Horinouchi Research Grant; Japan Leukemia Research Fund; Yasuda Memorial Medical Foundation; the Ichiro Kanehara Foundation; and the Research Clusters program of Tokushima University. Abe received research funding from Chuagai Pharmaceutical, Sanofi K.K., Pfizer Seiyaku K.K., Kyowa Hakko Kirin, MSD K.K., Astellas Pharma, Takeda Pharmaceutical, Teijin Pharma and Ono Pharmaceutical, and honoraria from Daiichi Sankyo Company. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Contributions: J.T. and M.A. designed the research and conceived the project. PCR was performed by J.T., H.T., A.O. and S.S.; flow cytometry by A.O., M.H. and T.H.; immunoblotting by J.T., H.T., M.H., A.O., A.B., T.H., S.N., M.A., S.S. and M.I.; transfection by J.T., H.T., M.H., A.O. and T.H.; and cell cultures by J.T., H.T., M.H., A.O., A.B., T.H., S.N., M.A., S.S., M.I., K.S., M.O., S.F., K.K. and H.M. J.T., H.T., M.H., A.O., T.H., S.N., M.H., I.E., T.H., T.M., and M.A. analyzed the data. J.T. and M.A. wrote the manuscript.